СПИСОК ЛИТЕРАТУРЫ.

1. Абоян, И. А. Тактика лечения больных раком предстательной железы в клинической стадии А, с гистологической верификацией диагноза после ТУР / И.А. Абоян, Э.Г. Левин, С.В. Павлов // Материалы пленума правления Российского общества урологов.

2. Аксель, Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России в 2003 г. / Е.М. Аксель // Онкоурология. - 2005. - № 1. - С. 6-9.

3. Аляев, Ю.Г. Молекулярная патология рака предстательной железы: диагностическая и прогностическая значимость основных маркеров / Ю.Г. Аляев, Е.А. Безруков, П.А. Шестиперов // Онкоурология. - 2006. - № 2. - C.45-51.

4. Аляев, Ю.Г. Расстройства мочеиспускания. Серия «Опыт клинической практики» / Ю.Г. Аляев, В.А. Григорян, З.К. Гаджиева. - М.: Литтерра, 2006. - 208 с.

5. Асаад, О. Диагностика и лечение урологических осложнений рака предстательной железы: обзор литературы / О. Асаад, В.В. Мешков // Международный Медицинский Журнал. - 2002. - № 4. - C. 22-27.

6. Варенцов, Г.И. Лечебная тактика при первично-множественном синхронном раке предстательной железы и мочевого пузыря у больных пожилого и старческого возраста / Г.И. Варенцов, Ю.М. Захматов, А.И. Корнев // Материалы Пленума Правления российского общества урологов. - М., 1999. - С. 215-217.

7. Гранов, А.М. Лучевая терапия в онкогинекологии и онкоурологии / под ред. чл.-кор. РАМН проф. А.М. Гранова, проф. В.Л. Винокурова. - СПб.: ООО «Издательство ФОЛИАНТ», 2002. - С. 304-305.

8. Дедов, И.И. Эндокринология: учебник / И.И. Дедов, Г.А. Мельниченко, В.В. Фадеев. - М.: Медицина, 2000. - 631 с.

9. Деятельность онкологической службы Санкт-Петербурга в 2006 г. / ред. В.М. Мерабишвили. - СПб., 2008. - 23 с.

10. Доброхотов, М.А. Место трансуретральной резекции в диагностике и комплексном лечении рака предстательной железы у больных пожилого и старческого возраста: автореф.

11.Заявка 2011138818/14 Российская Федерация, МПК A 61 B 18/2. Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты / Горелов В.П., Горелов С.И. ; заявители Горелов В.П., Горелов С.И. - № 2011138818/14; заявл. 21/09/2011; опубл. 27.03.13. - Режим доступа: http://www1.fips.ru/fips_servl/fips_servlet.

12. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. - М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. - 2014. - 250 с.

13.Зоря, О.В. Трансуретральная субтотальная «простатэктомия» у больных раком предстательной железы с высоким риском радикальных методов лечения: автореф. дис. ... канд. мед. наук / Зоря Ольга Владимировна. - М., 2006. - 31 с.

14. Качество жизни больных баланопоститом / В.А. Максимов, К.И. Забиров, Н.В. Марчук [и др.] // Врач. - 2008. - № 5. - С. 25-29.

15. Комяков, Б.К. Урология: учебник / Б.К. Комяков. - М.: ГЭОТАР-Медиа, 2013. - 488 с.

16. Лопаткин, Н.А. Руководство по урологии / Н.А. Лопаткин. - М.: Медицина, 1998. - 213 с.

17. Лоран, О.Б. Влияние доксазозина на функцию мочевого пузыря у больных доброкачественной гиперплазией предстательной железы / О.Б. Лоран, А.Е. Вишневский // Современные подходы к лечению гиперплазии простаты и эректильной дисфункции, материалы симпозиума (Омск, 23 марта 1999). - М., 2000. - С. 14-19.

18. Лоран, О.Б. Лечение расстройств мочеиспускания у больных доброкачественной гиперплазией простаты альфа-адреноблокаторами / О.Б. Лоран, Е.Л. Вишневский, А.Е. Вишневский. - М.: [б.и.], 1998. - 124 с.

19. Лоран, О.Б. Современные возможности лечения рака предстательной железы в стадии T3N0M0 (часть II) / О.Б. Лоран, Б.А. Томкевич // Урология. - 2004. - № 6. - P. 49-53.

20. Лоран, О.Б. Современные возможности медикаментозного лечения доброкачественной гиперплазии предстательной железы / О.Б. Лоран, А.Е.

21. Маринбах, Е.Б. Рак предстательной железы / Е.Б. Маринбах. - М.: Медицина, 1980. - 160 с.

22. Матвеев, Б.П. Рак предстательной железы / Б.П. Матвеев, Б.В. Бухаркин, В.Б. Матвеев. - М., 1999. - 156 с.

23. Мельников А.В. Послеоперационная острая задержка мочеиспускания: дис. ... канд. мед. наук / Мельников Александр Владимирович. - М., 2002. - 26 с.

24. Мерабишвили В.М. Онкологическая служба Санкт-Петербурга (оперативная отчетность за 2011-2012 годы, углубленная разработка базы данных регистра по международным стандартам). ПРР (IACR №221), том 18 / Под ред. В.М. Колабутина, А.М. Беляева. - СПб.: Коста. - 2013. - 364 с.

25. Мерабишвили, В.М. Динамика показателей 5-летней относительной выживаемости больных раком предстательной железы / В.М. Мерабишвили, К.Ю. Кротов // VII съезд онкологов и радиологов стран СНГ. Астана. Респ. Казахстан. - 2012. - С.16.

26. Метелев, B.B. Место лучевой терапии в комбинированном лечении больных раком предстательной железы: дис. ... д-ра. мед. наук / Метелев Виктор Васильевич. - СПб., 2005. - C. 98-101 с.

27. Неотложные состояния при раке простаты / Л.В. Шаплыгин, Д.В. Фурашов, Д.М. Монаков [и др.]: тезисы VI Всероссийской научно-

практической конференции «Актуальные вопросы лечения

онкоурологических заболеваний» // Онкоурология. - 2005. - Прил. «Комбинированное лечение онкоурологических заболеваний». - С.108.

28. Пат. 130854 Российская Федерация, МПК А 61 N 5/00. Установка для инсталляции радиоактивных имплантатов / Горелов В.П., Горелов С.И., Артюшкин А.В., Гудкин Г.В.; патентообладатели Горелов В.П., Горелов С.И., Артюшкин А.В. - № 2011138819/14, заявл. 21.09.11; опубл. 10.08.13.

- Режим доступа: http://www1.fips.ru/fips_servl/fips_servlet.

29. Переверзев, А.С. Рак простаты / А.С. Переверзев, М.И. Коган. - Харьков: Факт, 2004. - 231 с.

30. Пушкарь, Д.Ю. Биопсия предстательной железы / Д.Ю. Пушкарь, А.В. Говоров. - М.: ГОЭТАР-Медиа.

31. Справочное издание Урофлоуметрия / Е.Л. Вишневский, Д. Ю. Пушкарь, О.Б. Лоран [и др.]. - М.: Печатный Город, 2004. - 220 с.

32. Трансуретральная резекция при раке предстательной железы / В.Ю. Борщ, Г.И. Варенпов, Ю.М. Захматов [и др.] // Материалы Пленума Правления российского общества урологов. - М., 1999. - С. 212-214.

33. Урология по Дональду Смиту / под ред. Э. Танахо, Дж. Маканича; пер. с англ. - М.: Практика, 2005. - 819 с.

34. A dose-response study for I-125 prostate implants / R.G. Stock, N.N. Stone, A. Tabert [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 1998. - Vol. 41 (1). - P. 101-108.

35. A three-dimensional stereotactic device for computed tomography-guided invasive diagnostic and therapeutic procedures / P.G. Koutrouvelis, A. Louie, E. Lang [et al.] // Invest. Radiol. - 1993. - Vol. 28 (9). - P. 845-847.

36. Abrams, P. Urine flow studies / P. Abrams, M. Torrens // Urol. Clin. North. Am.

- 1979. - Vol. 6 (1). - P. 71-79.

37. Acute urinary complications after prostate iodine-125 brachytherapy: evaluation and risk factors / S. Mallick, R. Azzouzi, P. Bey [et al.] // Cancer Radiother. - 2002. - Vol. 6 (2). - P. 99-105.

38. Acute urinary retention secondary to carcinoma of the prostate. Is initial channel TURP benefitial? / D.J. Thomas, V.J. Balaji, M.J. Coptcoat [et al.] // JR SocMed. - 1992. - Vol. 85 (6). - P. 318-319.

39. Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5- year minimum follow-up / R.J. Amdur, J.T. Parsons, L.T. Fitzgerald [et al.] // Radiother. Oncol. - 1990. - N 18. - P. 235-246.

40. AJCC Cancer Staging Handbook / F.L. Greene, D.L. Page, I.D. Fleming [et al.]. - 6th ed. - New York: Springer, 2002. - P. 337-345.

41. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy / B.J. Davis, E.M. Horwitz, W.R. Lee [et al.] // Brachytherapy. - 2012. - Vol. 11 (1). - P. 6-19.

42. American Cancer Society.

43. American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer / J.P. Ciezki, I.C. Hsu, M. Abdel-Wahab [et al.] // Clin. Oncol. (R Coll Radiol). - 2012. - Vol. 24 (1). - P. 43-51.

44. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer / S.A. Rosenthal, N.H.J. Bittner, D.C. Beyer [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2011. - N 79. - P. 335-341.

45. An improved method for computerized tomography-planned transperineal 125iodine prostate implants / K. Wallner, S.T. Chiu-Tsao, J. Roy [et al.] // J. Urol. - 1991. - Vol. 146 (1). - P. 90-95.

46. Anderson, J. The role of antiandrogen monotherapy in the treatment of prostate cancer / J. Anderson // BJU Int. - 2003. - Vol. 91 (5). - P. 455-461.

47. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy / A. Hinerman-

Mulroy, G.S. Merrick [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2004. - Vol. 59 (5). - P. 1367-1382.

48. Arlandis Guzman, S. Voiding dysfunction after brachytherapy in patients with prostate cancer / S. Arlandis Guzman, M.A. Bonillo Garda, E. Broseta Rico // Arch. Esp. Urol. - 2009. - Vol. 62 (10). - P. 826-837.

49. Aronowitz, J.N. Dawn of prostate brachytherapy: 1915- 1930 / J.N. Aronowitz // Int. J. Radiat. Oncol. Biol. Phys. - 2002. - Vol. 54 (3). - P. 712-718.

50. Barringer, B.S. Radium in the treatment of prostatic carcinoma / B.S. Barringer // Ann. Surg. - 1924. - Vol. 80 (6). - P. 881-884.

51. Barringer, B.S. Treatment of prostatic carcinoma / B.S. Barringer // Bull. N. Y. Acad. Med. - 1943. - Vol. 19 (6). - P.

52. Barry, M.J. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia / M.J. Barry // Urology. - 2001. - Vol. 58 (6). - Suppl 1. - P. 25-32.

53. Bates, C.P. Continence and incontinence. A clinical study of the dynamics of voiding and of the sphincter mechanism / C.P. Bates // Ann. R. Coll. Surg. Engl. - 1971. - Vol. 49 (1). - P. 18-35.

54. Battermann, J.J. Results of permanent prostate brachytherapy, 13 years of experience at a single institution / J.J. Battermann, T.A. Boon, M.A. Moerland // Radiother. Oncol. - 2004. - Vol. 71 (1). - P. 23-28.

55. Bergoine, J. Premieres experiences sur le rat blan / J. Bergoine, L. Tribondeau // C. R. Soc. Biol. - 1904. - N 57. - P. 592-595.

56. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy / S.J. Khaksar, R.W. Laing, A. Henderson [et al.] // BJU Int. - 2006. - Vol. 98 (6). - P. 1210-1215.

57. Biochemical disease- free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide / R.J. Ellis, H. Zhou, E.Y. Kim [et al.] // Brachytherapy. - 2007. - Vol. 6(1). - P. 16-25.

58. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation / C.J. Rosser, R. Chichakli, L.B. Levy [et al.] // J. Urol. - 2002. - Vol. 168 (2). - P. 536-541.

59. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results / R.G. Stock, N.N. Stone, J.A. Cesaretti [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2006. - Vol. 64 (2). - P. 527-533.

60. Blasko, J.C. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications / J.C. Blasko, H. Ragde, P.D. Grimm. // Scand. J. Urol. Nephrol. Suppl. - 1991. - N 137. - P.113-118.

61. Block, T. Transperineal permanent seed implantation of “low-risk” prostate cancer: 5-year-experiences in 118 patients / T. Block, H. Czempiel, F. Zimmermann // Strahlenther Onkologie. - 2006. - Vol. 182 (11). - P. 666-671.

62. Bohn, G. L' influence du radium sur les animan ven voie de croissance / G. Bohn // C. R. Acad. Sci. Paris. - 1903. - N 136. - P. 1012-1013.

63. Bostwick, D.G., Pathology of prostate cancer // Prostate Cancer / eds. M.S. Ernstoff, J.A. Heaney, R.E. Peschel (eds.). - Cambridge and Oxford: Blackwell Science, Inc., 1998. - P. 15-41.

64. Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience / P.G. Koutrouvelis, D. Theodorescu, S. Katz [et al.] // J. Urol. - 2005. - Vol. 173 (1). - P. 82-85.

65. Brawley, O.W. Prostate cancer epidemiology in the United States / O.W. Brawley // World J. Urol. - 2012. - Vol. 30 (2). - Р.195-200.

66. Can the need for palliative transurethral prostatic resection in patients with advanced carcinoma of the prostate be predicted? / A. Sehgal, A. Mandhani, N. Gupta [et al.] // J. Endourol. - 2005. - Vol. 19 (5). - P. 546-549.

67. Cancer treatment and survivorship statistics, 2014 / C.E. DeSantis, C.C. Lin, A.B. Mariotto [et al.] // CA Cancer J Clin. - 2014. - Jun 1. - doi: 10.3322/caac.21235. - [Epub ahead of print].

68. Carcinoma of the prostate: local control with external beam radiation therapy / R.P. Gibbons, J.T. Mason, R.J. Correa Jr. [et al.] // J. Urol. - 1979. - N 121. - P. 310-312.

69. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer / A.V. D'Amico, R. Whittington, S.B. Malkowicz [et al.] // Mol. Urol. - 2000. - Vol. 4 (3). - P. 171-175.

70. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update / A.W. Partin, M.W. Kattan, E.N. Subong [et al.] // JAMA. - 1997. - Vol. 277 (18). - P. 1445-1451.

71. Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review / B. Schmitt, T.J. Wilt, P.F. Schellhammer [et al.] // Urology. - 2001. - Vol. 57 (4). - P. 727-732.

72. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group / P. Grimm, I. Billiet, D. Bostwick [et al.] // BJU Int. - 2012. - N 109. - Suppl. 1. - P. 22-29.

73. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate / A.V. D'amico, C.M. Tempany, D. Schultz [et al.] // Urology. - 2003. - Vol. 62 (6). - P. 1063-1067.

74. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men / W.J. Catalona, J.P. Richie, F.R. Ahmann [et al.] // J. Urol. - 1994. - Vol. 151 (5). - P. 1283-1290.

75. Complications of definitive radiotherapy for carcinoma of the prostate / M.V. Pilepich, C.A. Perez, B.J. Walz [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 1981. - N 7. - P. 1341-1348.

76. Crain, D.S. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer / D.S. Crain, C.L. Amling, C.J. Kane // J. Urol. - 2004. - N 171. - P. 668-671.

77. Critzand, F.A. 10-year disease-freesurvival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology / F.A. Critzand, K. Levinson // J. Urol. - 2004. - Vol. 172 (6 Pt 1). - P. 2232-2238.

78. Darget, R. Treatment of carcinoma of the prostate with radium / R. Darget // Urol. Cutaneous Rev. - 1948. - Vol. 52 (6). - P. 352-357.

79. Decline in bilateral orchiectomy for prostate cancer in Olmsted county, Minnesota, 1956-2000 / L.J. Melton 3rd, K.I. Alothman, S.J. Achenbach [et al.] // Mayo Clinic Proc. - 2001. - Vol. 76 (12). - P. 1199-1203.

80. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference / M. Roach 3rd, G. Hanks, H. Thames Jr. [et al.] // Int. J. Radiat. Oncol. Biol. Phys . - 2006. - Vol. 65 (4). - P. 965-974.

81. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition / A.J. Stephenson, M.W. Kattan, J.A. Eastham [et al.] // J. Clin. Oncol. - 2006. - Vol. 24 (24). - P. 3973-3978.

82. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multiinstitutional pooled analysis / E.M. Horwitz, H.D. Thames, D.A. Kuban [et al.] // J. Urol. - 2005. - Vol. 173 (3). - P. 797-802.

83. Desmond, A.D. Subcapsular orchiectomy under local anaesthesia. Technique, results and implications / A.D. Desmond, A.J. Arnold, K.J. Hastie // Br. J. Urol. - 1988. - Vol. 61 (2). - P. 143-145.

84. Differential diagnosis of prostatism: A 12-year retrospective analysis of symptoms, urodynamics and satisfaction with therapy / S.A. Kaplan, D.L. Bowers, A.E. Te [et al.] // J. Urol. - 1996. - Vol. 155 (4). - P. 1305-1308.

85. Does brachytherapy have a role in the treatment of prostate cancer? / P.D. Grimm, J.C. Blasko, H. Ragde [et al.] // Hematol. Oncol. Clin. North Am. - 1996. - Vol. 10 (3). - P. 653-673.

86. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? / N.N. Stone, D.T. Marshall, J.J. Stone [et al.] // J Urol. - 2010. - Vol.183(2). - P.634-9.

87. Does the outcome of prostate cancer patients with large prostates differ from small prostate size in permanent seed, low dose-rate brachytherapy? / S.H. Aaltomaa, V.V. Kataja, A. Raty [et al.] // Scand. J. Urol. Nephrol. - 2011. - Vol. 45 (5). - P. 339-345.

88. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer / F. Guedea, F. Aguilo, A. Polo [et al.] // Radiother. Oncol. - 2006. - Vol. 80 (1). - P. 57-61.

89. Early prostate cancer detection and potential for surgical cure in men with poorly differentiated tumors / M. Perrotti, F. Rabbani, P. Russo // Urology. - 1998. - Vol. 52 (1). - P. 106-110.

90. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013 / A. Heidenreich, P.J. Bastian, J. Bellmunt [et al.] // Eur Urol. - 2014. - Vol.65(1). -P.124-37.

91. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer // A. Heidenreich, P.J. Bastian, J. Bellmunt [et al.] // Eur Urol. - 2014. - Vol.65(2). - P.467-79.

92. Effects of pelvic rotation and needle angle on pubic arch interference during transperineal prostate implants / S.A. Tincher, R.Y. Kim, M.P. Ezekiel [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2000. - Vol. 47 (2). - P. 361-363.

93. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer / M. Han, A.W. Partin, S. Piantadosi [et al.] // J. Urol. - 2001. - Vol. 166 (2). - P. 416-419.

94. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer / D. Ash, A. Flynn, J. Battermann [et al.] // Radiother. Oncol. - 2000. - Vol. 57 (3). - P. 315-321.

95. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy / D.J. Schwartz, S.E. Schild, W.W. Wong [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2005. - Vol. 61 (1). - P. 60-63.

96. Factors influencing risk of acute urinary retention after TRUS- guided permanent prostate seed implantation / J. Crook, M. McLean, C. Catton [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2002. - Vol. 52 (2). - P. 453-460.

97. Factors influencing urinary symptoms 10 years after permanent prostate seed implantation / N.N. Stone, N.K. Gerber, S. Blacksburg [et al.] // J. Urol. - 2012. - Vol. 187 (1). - P. 117-123.

98. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy / N. Lee, C.S. Wuu, R. Brody [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2000. - Vol. 48 (5). - P. 1457-1460.

99. Factors predicting for urinary incontinence after prostate brachytherapy / McElveen T.L., F.M. Waterman, H. Kim [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2004. - Vol. 59 (5). - P. 1395-1404.

100. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy / S.G. Williams, J.L. Millar, G.M. Duchesne [et al.] // Radiother Oncol. - 2004. - Vol. 73 (1) - P. 33-38.

101. Five- year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer / M.J. Zelefsky, D.A. Kuban, L.B. Levy [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2007. - Vol. 67 (1). - P. 65-70.

102. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer / G. Kovacs, R. Potter, T. Loch [et al.] // Radiother. Oncol. - 2005. - Vol. 74 (2). - P. 137-148.

103. Gleason, D.F. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging / D.F. Gleason, G.T. Mellinger // J. Urol. - 1974. - Vol. 111 (1). - P. 58-64.

104. Global cancer statistics / A. Jemal, F. Bray, M.M. Center [et al.] // CA Cancer J Clin. - 2011. - Vol.61(2). - P.69-90.

105. Green, N. Prostate cancer: post-irradiation incontinence / N. Green, D. Treible, H. Wallack // J. Urol. - 1990. - Vol. 144 (2 Pt 1). - P. 307-309.

106. Guidelines on Prostate Cancer. European association of Urology / A. Heidenreich, M. Bolla, S. Joniau [et al.]. - European Association of Urology, 2010. - 163 p.

107. Hanks, G.E. The dissemination of cancer by transurethral resection of locally advanced prostate cancer / G.E. Hanks, S. Leibel, S. Kramer // J. Urol. - 1983. - Vol. 129 (2). - P. 309-311.

108. Henderson. A. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study / A. Henderson, S.E.M. Langley, R.W. Laing // Clin. Oncol. (R Coll Radiol). - 2003.

- Vol. 15 (6). - P. 318-321.

109. High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8-year follow-up / P.G. Koutrouvelis, J. Gillenwater, N. Lailas [et al.] // Radiother. Oncol. - 2003. - Vol. 67 (3). - P. 303-308.

110. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results / D.J. Demanes, R.R. Rodriguez, L. Schour [et al.] // Int. J. Radiat. Oncol. Biol. Phys.

- 2005. - N 61. - P. 1306-1316.

111. Huggins, C. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland / C. Huggins, R.E. Stevens Jr., C.V. Hodges // Arch. Surg. - 1941. - N 43. - P. 209-223.

112. Huggins, C. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate / C. Huggins, C.V. Hodges // J. Urol. - 2002. - Vol. 167 (2P 2). - P. 948-951.

113. Ikeda, T. Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review / T. Ikeda, K. Shinohara // Int. J. Urol. - 2009. - Vol. 16 (6). - P. 558-560.

114. Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma / M.J. Zelefsky, W.F. Jr. Whitmore, S.A. Leibel [et al.] // J. Urol. - 1993. - Vol. 150 (6). - P. 1860-1864.

115. Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials / G. Rodrigues, K. Bae, M. Roach [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2011. - Vol. 80 (2). - P. 445-452.

116. Improvement of lower urinary tract symptoms in patients with prostate cancer treated with maximal androgen blockade / Zhong K., Li W., Gui M. [et al.] // Zhong Nan Da Xue Xue Bao Yi Xue Ban. - 2011. - Vol.36(9). - P.849-53.

117. Influence of prostate volume on dosimetry results in real-time 125I seed implantation / L.K. McNeely, N.N. Stone, J. Presser [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2004. - Vol. 58 (1). - P. 292-299.

118. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma / H. Ragde, J.C. Blasko, P.D. Grimm [et al.] // Cancer. - 1997. - N 80. - P. 442-453.

119. Iodine-125 Seed Implantation and Deferred Transurethral Resection of the Prostate for Patients With Lower Urinary Tract Symptoms and Localized Prostate Cancer / R. Liu, F. Luo, Z. Zhang [et al.] // Clin. Genitourin Cancer. - 2013. -Vol. 11(3). - P. 251-255.

120. Irradiation of carcinoma of the prostate localized to the pelvis: analysis of tumor response and prognosis / C.A. Perez, B.J. Walz, F.R. Zivnuska [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 1980. - N 6. - P. 555-563.

121. Jolleys, J.V. Urinary symptoms in the community: how bothersome are they? / J.V. Jolleys // Br. J. Urol. - 1994. - Vol. 74 (5). - P. 551-555.

122. Koutrouvelis, P.G. Three-dimensional stereotactic posterior ischiorectal space computerized tomography guided brachytherapy of prostate cancer: a preliminary report / P.G. Koutrouvelis // J. Urol. - 1998. - Vol. 159 (1). - P. 142-145.

123. Lee, W.R. The role of androgen deprivation therapy combined with prostate brachytherapy / W.R. Lee // Urology. - 2002. - Vol. 60 (3). - Suppl 1. - P. 3944.

124. Lepor, H. The pathophysiology of lower urinary tract symptoms in the ageing male population / H. Lepor // Br. J. Urol. - 1998. - N 81. - Suppl 1. - P. 29-33.

125. Long-term potency preservation following brachytherapy for prostate cancer / K.M. Snyder, R.G. Stock, M. Buckstein [et al.] // BJU Int. - 2012. - Vol. 110 (2). - P. 221-225.

126. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease / H.B. Carter, J.D. Pearson, E.J. Metter [et al.] // JAMA.

- 1992. - Vol. 267 (16). - P. 2215-2220.

127. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection / A.V. Peddada, S.B. Jennings, P.O. Faricy [et al.] // J. Urol. - 2007. - Vol. 178 (5). - P. 1963-1967.

128. Low-dose rate brachytherapy for men with localized prostate cancer / F. Peinemann,U. Grouven, L.G. Hemkens [et al.] // Cochrane Database Syst. Rev.

- 2011. - Vol. 6 (7). - CD008871.

129. Mansfield, J.T. Does transurethral resection of the prostate compromise the radical treatment of prostate cancer? / J.T.Mansfield, R.A. Stephenson // Semin. Urol. Oncol. - 1996. - Vol. 14 (3). - P. 174-177.

130. Maximal androgen blockade for advanced prostate cancer / B. Schmitt, C.L. Bennett, J. Seidenfeld [et al.] // Cochrane Database Syst. Rev. - 2000. - N 2. - D001526.

131. Mazur, A.W. Efficacy and morbidity of "channel" TURP / A.W. Mazur, I.M. Thompson // Urology. - 1991. - Vol. 38 (6). - P. 526-528.

132. McConnel, J.D. Benign prostatic hyperplasia / J.D. McConnel // J. Urol. - 1995. - Vol. 154 (2 Pt 1). - P. 402-403.

133. McLeod, D.G. Hormonal therapy: historical perspective to future directions / D.G. McLeod // Urology. - 2003. - Vol. 61 (2 Suppl 1). - P. 3-7.

134. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer / W.J. Catalona, D.S. Smith, T.L. Ratliff [et al.] // N. Engl. J. Med. - 1991. - Vol. 324 (17). - P. 1156-1161.

135. Merrick, G.S. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland / G.S. Merrick, K.E. Wallner, W.M. Butler // J. Urol. - 2003. - Vol. 169 (5). - P. 1643-1652.

136. Metastatic liver tumor arising from prostatic cancer following transurethral resection of the prostate - a report of two cases / N. Yamamoto, X. Zhang, S. Soramoto [et al.] // Gan To KagakuRyoho. - 2001. - Vol. 28 (4). - P. 545-548.

137. Modified TURP for men with moderate LUTS prior to brachytherapy is safe and feasible / P. Brousil, M. Hussain, M. Lynch [et al.] // BJU Int. - 2014. - May 6. -doi: 10.1111/bju. 12798. - [Epub ahead of print].

138. Mommsen, S. Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention / S. Mommsen, L. Petersen // Scand. J. Urol. Nephrol. - 1994. - Vol. 28 (4). - P. 401-404.

139. Morris, W.J. Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room? / W.J. Morris, R. Halperin, I. Spadinger // Brachytherapy. - 2010. - Vol. 9 (4). - P. 289-292.

140. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy / A.V. Taira, G.S. Merrick, R.W. Galbreath [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2010. - Vol. 76 (2). - P. 349-354.

141. NCI. Prostate Cancer Treatment-treatment option overview. National Cancer Institute Web site.-http://www.cancer.gov/cancertopics/pdq/treatment/proctate

142. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy / J.F. Langenhuijsen, E.N. van Lin, A.L. Hoffmann [et al.] // Urol Oncol. - 2011. - Vol.29(1). - P.52-7.

143. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity / K.R. Blank, R. Whittington, B. Arjomandy [et al.] // Cancer J. Sci. Am. - 1999. - Vol. 5 (6). - P. 370-373.

144. Neoadjuvant Hormonal Therapy Use and the Risk of Death in Men with Prostate Cancer Treated with Brachytherapy Who Have No or at Least a Single Risk Factor for Coronary Artery Disease / A. Nanda, M.H. Chen, B.J. Moran [et al.] // Eur. Urol. - 2014. - Vol. 65 (1). - P. 177-185.

145. Nomograms to predict late urinary toxicity after prostate cancer radiotherapy /

R. Mathieu, J.D. Arango, V. Beckendorf [et al.] // World J Urol. - 2014. - Vol.32(3). - P.743-51.

146. Oefelein, M.G. Effective testosterone suppression for patients with prostate cancer: is there a best castration? / M.G. Oefelein, M.I. Resnick // Urology. - 2003. - Vol. 62 (2). - P. 207-213.

147. One-step customized transurethral resection of the prostate and permanent implant brachytherapy for selected prostate cancer patients: technically feasible but too toxic / J.M. Cosset, E. Barret, P. Castro-Pena [et al.] // Brachytherapy. - 2011. - Vol. 10 (1). - P. 29-34.

148. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease / B.T. Helfand, A.K. Mongiu, D. Kan [et al.] // BJU Int. - 2009. - Vol. 104 (3). - P. 304-309.

149. Park, D.S. Current status of brachytherapy for prostate cancer / D.S. Park // Korean J. Urol. - 2012. - Vol. 53 (11). - P. 743-749.

150. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy / N. Tanaka, I. Asakawa,

S. Anai [et al.] // Radiat. Oncol. - 2013. - Vol. 8 (1). - P. 25.

151. Permanent iodine 125 implant brachytherapy in localized prostate cancer: results of the first 4 years of experience / F. Bladou, N. Salem, M. Simonian- Sauve [et al.] // Prog. Urol. - 2004. - Vol. 14 (3). - P. 345-352.

152. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience / A.G. Martin, J. Roy, L. Beaulieu [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2007. - Vol. 67 (2). - P. 334-341.

153. Peschel, R. Pubic arch interference in permanent prostate implant patients / R. Peschel, C. King, K. Roberts // J. Brachytherapy Int. - 1998. - N 14. - P. 241248.

154. Peschel, R.E. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer / R.E. Peschel, J.W. Colberg // Lancet Oncol. - 2003. - Vol. 4 (4). - P. 233-241.

155. Prada, P.J. I125 low dose rate brachytherapy in localized prostate cancer: preliminary results after 5 years / P.J. Prada, M. Hevia, G. Juan // Arch. Esp. Urol. - 2005. - Vol. 58 (3). - P. 213-226.

156. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience / M.J. Zelefsky, J.F. Chou, X. Pei [et al.] // Brachytherapy. - 2012. - Vol. 11 (4). - P. 245-249.

157. Predicting pubic arch interference in prostate brachytherapy on transrectal ultrasonography-computed tomography fusion images / J. Fukada, N. Shigematsu, J. Nakashima, T. Ohashi [et al.] // J. Radiat. Res. - 2012. - Vol. 53 (5). - P. 753-759.

158. Predicting the severity of acute urinary toxicity after brachytherapy with iodine-125 for localized prostate cancer / K. Takeda, K. Jingu, M. Koto [et al.] // Tohoku J. Exp. Med. - 2011. - Vol. 223 (1). - P. 55-60.

159. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma / M.J. Wehle, S.W. Lisson, S.J. Buskirk [et al.] // Mayo Clin. Proc. - 2004. - Vol. 79 (3). - P. 314-317.

160. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients / M. Keyes, S. Miller, V. Moravan [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2009. - N 73. - P. 1023-1032.

161. Predictive factors of urinary retention following prostate brachytherapy / J. Bucci, W.J. Morris, M. Keyes [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2002.

- Vol. 53 (1). - P. 91-98.

162. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL / M. Garzotto, R.G. Hudson, L. Peters [et al.] // Cancer.

- 2003. - Vol. 98 (7). - P. 1417-1422.

163. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter / I.M. Thompson, D.K. Pauler, P.J. Goodman [et al.] // N. Engl. J. Med. - 2004. - Vol. 350 (22). - P. 2239-2246.

164. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo- controlled randomized study / M.A. Elshaikh, J.C. Ulchaker, C.A. Reddy [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2005. - Vol. 62 (1). - P. 164-169.

165. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy / G.S. Merrick, W.M. Butler, K.E. Wallner [et al.] // Urology. - 2002. - Vol. 60 (4). - P. 650-655.

166. Prostate antigen: a new potential marker for prostatic cancer / M.C. Wang, L.D. Papsidero, M. Kuriyama [et al.] // Prostate. - 1981. - Vol. 2 (1). - P. 8996.

167. Prostate Cancer Trialists5 Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials / Prostate Cancer Trialists’ Collaborative Group // Lancet. - 2000. - Vol. 355 (9214). - P. 1491-1498.

168. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup / P.G.

Koutrouvelis, N. Lailas, S. Katz [et al.] // J. Urol. - 2003. - Vol. 169 (4). - P. 1331-1336.

169. Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines / J.L. Mohler, A.J. Armstrong, R.R. Bahnson [et al.] // JNCCN. - 2012. - N 10. - Р. 1081-1187.

170. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy / R. Kucway, F. Vicini, R. Huang [et al.] // J. Urol. - 2002. - Vol. 167 (6). - P. 2443-2447.

171. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate / T.A. Stamey, N. Yang, A.R. Hay [et al.] // N. Engl. J. Med. - 1987. - Vol. 317 (15). - P. 909-916.

172. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy / J. Joseph, B. Al-Qaisieh, D. Ash [et al.] // BJU Int. - 2004. - Vol. 94 (9). - P. 1235-1238.

173. Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapy / R.P. Pal, J.R. Bhatt, M.A. Khan [et al.] // Brachytherapy. - 2011. - N 10. - P. 107-116.

174. Purification of a human prostate specific antigen / M.C. Wang, L.A. Valenzuela, G.P. Murphy [et al.] // Invest. Urol. - 1979. - Vol. 17 (2). - P. 159163.

175. Quantifying the change in endorectal magnetic resonance imaging- defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer / M.V. Sanghani, D. Schultz, C.M. Tempany [et al.] // Urology. - 2003. - Vol. 62 (3). - P. 487-491.

176. Radiation therapy and pelvic node dissection in the management of cancer of the prostate / B.S. Hilaris, W.F. Jr. Whitmore, M.A. Batata [et al.] // Am. J. Roentgenol. Radium Ther. Nucl. Med. - 1974. - Vol. 121 (4). - P. 832-838.

177. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma / A.A. Aizer, J.B. Yu, J.W. Colberg [et al.] // Radiother. Oncol. - 2009. - Vol. 93 (2). - P. 185-191.

178. Real-time US versus CT determination of pubic arch interference for brachytherapy/ J.G. Strang, D.J. Rubens, R.A. Brasacchio [et al.] // Radiology. - 2001. - Vol. 219 (2). - P. 387-393.

179. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making / M.G. Oefelein, A. Feng, M.J. Scolieri [et al.] // Urology. - 2000. - Vol. 56 (6). - P. 1021-1024.

180. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following I prostate brachytherapy / C. Martens, G. Pond, D. Webster [et al.] // Brachytherapy. - 2006. - Vol. 5 (1). - P. 9-13.

181. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer: Evidence Report/Technology Assessment No. 4 / J. Seidenfeld, D.J. Samson, N. Aronson [et al.] // AHCPR Publication No. 99-E0012. - May 1999. - Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville, MD.

182. Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia / M.R. Feneley, W.D. Dunsmuir, J. Pearce [et al.] // Urology. - 1996. - Vol. 47 (5). - P. 658-663.

183. Retrospective evaluation of urinary continence in patients submitted to brachytherapy after transurethral resection of the prostate gland / D.R. Claros, J.A. Correia, L.R. Ferreira [et al.] // Actas. Urol. Esp. - 2009. - Vol. 33 (4). - P. 356-360.

184. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study / J. Locke, W. Ellis, K. Wallner [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2002. - Vol. 52 (3). - P. 712-719.

185. Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy / Y. Kwok, S.J. DiBiase, P.P. Amin [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2002. - Vol. 53 (3). - P. 588-594.

186. Role of transurethral resection in dissemination of cancer of prostate / E.S. Levine, V.J. Cisek [et al.] // Urology. - 1986. - Vol. 28 (3). - P. 179-183.

187. Role of transurethral resection of the prostate in hematogenously disseminated metastasis / R. Bhatti, G. Baumgartner, P. Guinan [et al.] // Urol. Int. - 1988. - Vol. 43 (1). - P. 29-31.

188. Schmid, H.P. The problem of obstruction, in prostate cancer / H.P. Schmid // Urol. Res. - 1991. - Vol. 19 (6). - P. 323-326.

189. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity / M. Beekman, G.S. Merrick, W.M. Butler [et al.] // Urology. - 2005. - Vol. 66 (6). - P.1266-1270.

190. Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis / M. J0nler, M.A. Ritter, R. Brinkmann [et al.] // Urology. -1994. - Vol. 44 (6). - P. 876-882.

191. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy / S. Gutman, G.S. Merrick, W.M. Butler [et al.] // BJU Int. - 2006. - Vol. 97 (1). - P. 62-68.

192. Shrivastava, S. Brachytherapy - perspectives in evolution: take it with a bag of salt... / S. Shrivastava // J. Cancer Res. Ther. - 2005. - Vol. 1 (2). - P. 73-74.

193. Sobin, L.H. International Union Against Cancer (UICC) TNM Classification Of Malignant Tumors / Sobin LH, Wittekind C. - 6th ed. - NY: Wiley-Liss, 2002. - 239 p.

194. Stock, R.G. Importance of post-implant dosimetry in permanent prostate brachytherapy / R.G. Stock, N.N. Stone // Eur. Urol. - 2002. - Vol. 41 (4). - P. 434-439.

195. Stone, N.N. Complications following permanent prostate brachytherapy / N.N. Stone, R.G. Stock // Eur. Urol . - 2002. - N 41. - P. 427-433.

196. Stone, N.N. Prostate brachitherapy in patients with prostate volumes > 50 cm (3): dosimetric analisis of implant quality / N.N. Stone, R.G. Stock // Int. J. Radiat. Oncol. Biol. Phys. - 2000. - N 46. - P. 1199-1204.

197. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer / J. Crook, H. Lukka, L. Klotz [et al.] // CMAJ. - 2001. - Vol. 164 (7). - P. 975-981.

198. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma / D.J. Samson, J. Seidenfeld, B. Schmitt [et al.] // Cancer. - 2002. - Vol. 95 (2). - P. 361-376.

199. Temporal resolution of urinary morbidity following prostate brachytherapy / G.S. Merrick, W.M. Butler, J.H. Lief [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2000. - Vol. 47 (1). - P. 121-128.

200. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience / J.E. Sylvester, J.C. Blasko, P.D. Grimm [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2003. - Vol. 57 (4). - P. 944-952.

201. Terk, M.D. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate / M.D. Terk, R.G. Stock, N.N. Stone // J. Urol. - 1998. - Vol. 160 (4). - P. 1379-1382.

202. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of Prostatic Carcinoma / J.I. Epstein, W.C. Jr. Allsbrook, M.B. Amin [et al.] // Am. J. Surg. Pathol. - 2005. - Vol. 29. - P. 1228-1242.

203. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy / G.S. Merrick, W.M. Butler, K.E. Wallner [et al.] // Brachytherapy. - 2004. - Vol. 3 (1). - P. 22-29.

204. The effect of radiotherapy on urethral obstruction from carcinoma of the prostate / P. Wells, P.J. Hoskin, J. Towler [et al.] // Br. J. Urol. - 1996. - Vol. 78 (5). - P. 752-755.

205. The effect of transurethral resection on the incidence of osseous, prostatic metastasis / D.A. Kuban, A.M. el-Mahdi, P.F. Schellhammer [et al.] // Cancer. - 1985. - Vol. 56 (4). - P. 961-964.

206. The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer / S. Ebara, D. Manabe, Y. Kobayashi [et al.] // Acta. Med. Okayama. - 2007. - Vol. 61 (6). - P. 335-340.

207. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer / G.S. Merrick, W.M. Butler, K.E. Wallner [et al.] // Cancer J. - 2005. - Vol. 11 (3). - P. 234-240.

208. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy / J.A. Taylor III, S.G. Koff, D.A. Dauser [et al.] // BJU Int. - 2006. - Vol. 98 (3). - P. 540-543.

209. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL / N.L. Dallas, P.R. Malone, A. Jones [et al.] // BJU Int. - 2012. - Vol. 110 (3). - P. 383-390.

210. The risk of distant metastases after transurethral resection of the prostate versus needle biopsy in patients with localized pro state cancer / R.B. Meacham, P.T. Scardino, G.S. Hoffman [et al.] // J. Urol. - 1989. - Vol. 142 (2 Pt 1). - P. 320-325.

211. There an Increase in Genitourinary Toxicity in Patients Treated With Transurethral Resection of the Prostate and Radiotherapy?: A Systematic Review / H. Ishiyama, T. Hirayama, P. Jhaveri [et al.] // Am. J. Clin. Oncol. - 2012. - Jun 14. - [Epub ahead of print].

212. TNM classification of malignant tumors. UICC International Union Against Cancer / L.H. Sobin, M. Gospodariwicz, C. Wittekind (eds). - 7th ed. - Wiley- Blackwell, 2009. - P. 243-248.

213. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography / H.H. Holm, N. Juul, J.F. Pedersen [et al.] // J. Urol.

- 1983. - Vol. 130 (2). - P. 283-286.

214. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy / C. Salembier, P. Lavagnini, P. Nickers [et al.] // Radiother Oncol. - 2007. - Vol. 83 (1). - P. 3-10.

215. Two-step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low- to intermediate-risk prostate cancer / A.N. Ivanowicz, C.M. Wakeman, R.T. Hubbard [et al.] // Brachytherapy. - 2012. - Vol. 11 (6). - P. 483-488.

216. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy / M.A. Kollmeier, R.G. Stock, J. Cesaretti [et al.] // J. Urol. - 2005. - Vol. 173 (3). - P. 808-812.

217. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation / D.Y. Gelblum, L. Potters, R. Ashley [et al.] // Int. J. Radiat. Oncol. Biol. Phys - 1999. - Vol. 45 (1). - P. 59-67.

218. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy / J. Bellon, K. Wallner, W. Ellis [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 1999. - Vol. 43 (3). - P. 579-581.

219. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial / W.J. Catalona, A.W. Partin, K.M. Slawin [et al.] // JAMA. - 1998. - Vol. 279 (19). - P. 1542-1547.

220. Use of TRUS to predict pubic arch interference of prostate brachytherapy / K. Wallner, W. Ellis, K. Russell [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 1999.

- Vol. 43 (3). - P. 583-585.

221. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer / M.L. Blute, E.J. Bergstralh, A.W. Partin [et al.] // J. Urol. - 2000. - Vol. 164 (5). - P. 1591-1595.

222. Wallner, K. Iodine 125 brachytherapy for early stage prostate cancer: new techniques may achieve better results / K. Wallner // Oncology (Williston Park). -1991. - Vol. 5 (10). - P. 115-122.

223. Walsh, P.C. Physiologic basis for hormonal therapy in carcinoma of the prostate / P.C. Walsh // Urol. Clin North Am. - 1975. - Vol. 2 (1). - P. 125-140.

224. Whitmore, W.F. Jr. Retropubic implantation to iodine 125 in the treatment of prostatic cancer. / W.F. Jr. Whitmore, B. Hilaris, H. Grabstald // J. Urol. - 2002. - Vol. 167 (2 Pt 2). - P. 981-983.

225. Whittington, R. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate / R. Whittington // Int. J. Radiat. Oncol. Biol. Phys. - 1999. - Vol. 44 (5). - P. 1107-1110.

226. Zelefsky, M.J. Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer / M.J. Zelefsky, W.F.Jr. Whitmore // J. Urol. - 1997. - Vol. 158 (1). - P. 23-29.

227. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)1 brachytherapy / P.D. Grimm, J.C. Blasko, J.E. Sylvester [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2001. - Vol. 51 (1). - P. 31-40.

228. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice / J. Sharkey, A. Cantor, Z. Solc [et al.] // Brachytherapy. - 2005. - Vol. 4 (1). - P. 34-44.

229. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer / L. Potters, C. Morgenstern, E. Calugaru [et al.] // J. Urol. - 2005. - Vol. 173 (5). - P. 1562-1566.

230. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial / K. Wallner, G. Merrick, L. True [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2003. - Vol. 57 (5). - P. 12971303.